Redox announced today that it raised $9 million in its Series B financing round, which was led by RRE Ventures.

According to a release, Redox, which processes approximately 1 million clinical messages each day, will use the money to accelerate its product roadmap.

“The free flow of healthcare data is critical to accelerating the discovery and adoption of solutions that improve our health,” Redox President and Co-Founder Niko Skievaski said in a statement. “We couldn’t be more excited to be ushering forth this future of technology-enabled healthcare.”

.406 Ventures, HealthX Ventures and Flybridge Capital Partners also participated in the financing round.